Inamrinone Lactate Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 10 mg/mL
Reference Brands: Generic formulations marketed under different names
Category:
Heart Disorder
Inamrinone Lactate is available in Injection
and strengths such as 10 mg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Inamrinone Lactate is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Inamrinone Lactate can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Inamrinone, also known as amrinone and marketed under the brand name Inocor, is a phosphodiesterase-3 (PDE3) inhibitor used in the management of congestive heart failure. It exerts a positive inotropic effect, enhancing the contractility of cardiac muscle and improving cardiac output in patients with heart failure. The drug achieves this by selectively increasing high-gain calcium-induced calcium release (CICR) within cardiac myocytes, which promotes stronger heart contractions. This effect is mediated through phosphorylation pathways involving cAMP-dependent protein kinase A (PKA) and Ca²⁺/calmodulin-dependent kinase, resulting in improved cardiac function.
Inamrinone is administered intravenously under strict medical supervision, typically in hospital or critical care settings, and is used for short-term management of severe or acute heart failure in patients who do not adequately respond to conventional therapies. By enhancing myocardial contractility and reducing vascular resistance, inamrinone provides symptomatic relief and can improve hemodynamic parameters in critically ill patients, making it an important therapeutic option in advanced heart failure management.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing